Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced today that it has commenced an underwritten public offering of $100.0 million of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of common stock offered